Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 23.48 CNY -2.29%
Market Cap: 38.3B CNY
Have any thoughts about
Humanwell Healthcare Group Co Ltd?
Write Note

Humanwell Healthcare Group Co Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Humanwell Healthcare Group Co Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Humanwell Healthcare Group Co Ltd
SSE:600079
Research & Development
-ÂĄ1.6B
CAGR 3-Years
-23%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-ÂĄ2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-ÂĄ197m
CAGR 3-Years
-24%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-ÂĄ5.8B
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-ÂĄ333.6m
CAGR 3-Years
-10%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-ÂĄ712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
38.3B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
37.19 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Humanwell Healthcare Group Co Ltd's Research & Development?
Research & Development
-1.6B CNY

Based on the financial report for Sep 30, 2024, Humanwell Healthcare Group Co Ltd's Research & Development amounts to -1.6B CNY.

What is Humanwell Healthcare Group Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-20%

Over the last year, the Research & Development growth was -16%. The average annual Research & Development growth rates for Humanwell Healthcare Group Co Ltd have been -23% over the past three years , -20% over the past five years .

Back to Top